Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 52,200 shares, a decrease of 41.9% from the May 31st total of 89,900 shares. Currently, 1.8% of the company’s shares are sold short. Based on an average trading volume of 623,800 shares, the short-interest ratio is currently 0.1 days.

Ainos Trading Down 1.9 %

Ainos stock traded down $0.02 during mid-day trading on Friday, hitting $0.83. 11,436 shares of the stock were exchanged, compared to its average volume of 1,281,887. Ainos has a 12 month low of $0.77 and a 12 month high of $6.10. The company has a quick ratio of 0.28, a current ratio of 0.32 and a debt-to-equity ratio of 0.10. The firm’s fifty day simple moving average is $0.97 and its two-hundred day simple moving average is $1.27.

Ainos (NASDAQ:AIMD) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.57) EPS for the quarter. Ainos had a negative net margin of 15,348.14% and a negative return on equity of 55.38%. The firm had revenue of $0.02 million for the quarter.

About Ainos

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.